Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Le DT, et al. Among authors: springett g. J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584002 Free PMC article. Clinical Trial.
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Daud AI, et al. Among authors: springett g. J Clin Oncol. 2015 Mar 20;33(9):1060-6. doi: 10.1200/JCO.2014.57.5027. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605849 Clinical Trial.
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Daud AI, et al. Among authors: springett gm. Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16. Clin Cancer Res. 2012. PMID: 22179664 Clinical Trial.
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP. Rashid OM, et al. Among authors: springett g. Ann Surg Oncol. 2016 Apr;23(4):1371-9. doi: 10.1245/s10434-015-5006-1. Epub 2015 Dec 10. Ann Surg Oncol. 2016. PMID: 26661409
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. Fracasso PM, et al. Clin Cancer Res. 2007 Feb 1;13(3):986-93. doi: 10.1158/1078-0432.CCR-06-1542. Clin Cancer Res. 2007. PMID: 17289894 Clinical Trial.
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Homsi J, et al. Among authors: springett g. Clin Cancer Res. 2007 Oct 1;13(19):5855-61. doi: 10.1158/1078-0432.CCR-06-2821. Clin Cancer Res. 2007. PMID: 17908979 Clinical Trial.
58 results